Enliven Therapeutics, Inc. cash flow to debt ratio of -17.62K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Enliven Therapeutics, Inc.'s free cash flow has increased -3.79% from $-73.24M last year to $-70.46M, signaling increasing performance

Enliven Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Enliven Therapeutics, Inc. has insufficient data to evaluate this check.

Enliven Therapeutics, Inc. has a net cash position, so leverage is healthy.

Enliven Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Enliven Therapeutics, Inc. has insufficient data to evaluate this check.

Enliven Therapeutics, Inc.'s short-term assets of $474.88M exceed its short-term liabilities of $16.57M

Enliven Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Enliven Therapeutics, Inc.'s return on equity of -18.55%, is lower than 15.00%, indicating bad performance

Enliven Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Enliven Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Enliven Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Enliven Therapeutics, Inc. has negative free cash flow, indicating cash burn

Enliven Therapeutics, Inc.'s yearly earnings has decreased 16.48% since last year from $-89.02M to $-103.69M, signaling decreasing performance

Enliven Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -13.88% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Enliven Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Enliven Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Enliven Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Enliven Therapeutics, Inc. has insufficient data to evaluate this check.

Enliven Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Enliven Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Enliven Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Enliven Therapeutics, Inc. has insufficient data to evaluate this check.

Enliven Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Enliven Therapeutics, Inc. has a price-to-book ratio of 4.39x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Enliven Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue